Systemic retinoids: chemoprevention of skin cancer in transplant recipients.
Solid organ transplant recipients (OTRs) have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. Chemoprevention strategies are focused on reducing and delaying the development of skin cancer in these patients. Although systemic retinoids are widely used in OTRs, few randomized controlled trials have been performed. Limited data suggest that acitretin may have a beneficial role in high-risk OTRs. Since rebound flares occur upon discontinuation of retinoids, chemoprevention should be viewed as a lifelong therapy. Further studies are required to establish the efficacy and long-term safety of systemic retinoids as chemopreventive agents for high-risk transplant recipients.
Hardin
J
J
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Mydlarski
P R
PR
D017255:Acitretin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D004347:Drug Interactions; D006801:Humans; D015994:Incidence; D016377:Organ Transplantation; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D012176:Retinoids; D017255:Acitretin